KalVista Pharmaceuticals, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for KALV, updated each market day.
KALV AI Sentiment
AI sees no strong directional signal for KalVista Pharmaceuticals, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About KalVista Pharmaceuticals, Inc. Common Stock
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
Sector
Exchange
Market Cap
$1,021,888,615
Cap Tier
Employees
270
Headquarters
FRAMINGHAM, MA
Listed Since
April 9, 2015
Website
KALV Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
KALV Volatility
KalVista Pharmaceuticals, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
